Amol Akhade

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Amol Akhade
May 8, 2025, 16:44 | Insight
Amol Akhade highlights key trials on neoadjuvant chemotherapy in pancreatic cancer
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared on X: "Neoadjuvant chemo…
May 8, 2025, 12:43 | Blog
Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
May 7, 2025, 07:31 | Blog
Amol Akhade: CDK4/6 Rechallenge Trials - What Works and What Doesn’t?
Amol Akhade, Consultant Medical Oncologist Hemato-Oncologist at Suyog Cancer Clinics, shared on LinkedIn: "CDK4/6 Rechallenge Trials:…
May 6, 2025, 18:24 | Blog
Amol Akhade: We Need More Global Oncologist to Participate in This
Amol Akhade, Consultant Medical Oncologist Hemato-Oncologist at Suyog Cancer Clinics, shared on X: "We need…
May 6, 2025, 10:45 | Drugs
Amol Akhade: Oral SERDs and PROTACs in ER+/HER2– Metastatic Breast Cancer - Trial Landscape Update
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
May 6, 2025, 05:37 | Insight
Amol Akhade: ASCO 2025 Guideline Update - mCRPC Treatment Sequencing Simplified
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
May 5, 2025, 10:37 | Blog
Amol Akhade Launches Clinician Poll on Adjuvant Therapy for Breast Cancer
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
May 5, 2025, 06:06 | Blog
Amol Akhade Shares Survey on Impact of Social Media on Oncology Practice
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
May 5, 2025, 03:27 | Blog
Amol Akhade: ASCO 2025 mCRPC Guideline Update - What’s new in sequencing
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
May 2, 2025, 17:12 | Science
Amol Akhade: Should We Abandon Routine Cancer Surveillance?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Apr 30, 2025, 12:46 | Science
New HER2 Targeted Therapy Alert! - Amol Akhade
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Apr 30, 2025, 10:53 | Blog
Amol Akhade: Aumolertinib and Chemotherapy, A New Challenger to Osimertinib?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
Apr 30, 2025, 09:55 | Blog
Amol Akhade: Next-generation KRAS G12C inhibitors are reshaping precision oncology
Amol Akhade, Senior Consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
Apr 30, 2025, 08:50 | Science
Updates from AACR25 by Amol Akhade
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared an updates from…
Apr 29, 2025, 17:41 | Insight
Amol Akhade: New HER2-targeted therapy breakthrough in NSCLC
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Apr 29, 2025, 11:13 | Blog
Posts Not to Miss from AACR 2025: Part 2
The AACR Annual Meeting is one of the biggest events in the world of cancer research—bringing together…
Apr 29, 2025, 04:40 | Blog
Amol Akhade: Exciting update from AACR25
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, posted on LinkedIn: "Exciting…
Apr 28, 2025, 13:16 | Insight
Amol Akhade: Insights on KEYNOTE-689 immunotherapy breakthrough in non-metastatic HNSCC at AACR 2025
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Apr 26, 2025, 00:17 | Blog
Amol Akhade: Excited for the positive news on PFS for Destiny 09
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Apr 25, 2025, 18:48 | Science
Amol Akhade: Shining light on real-world HER2+ breast cancer care
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Apr 25, 2025, 11:15 | Blog
Amol Akhade: Data to look forward at AACR2025
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
Apr 23, 2025, 19:57 | Blog
Amol Akhade: Which ADC target in SCLC holds the most promise?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospital,…
Apr 22, 2025, 10:51 | Blog
Amol Akhade: Sacituzumab govitecan plus pembrolizumab shows PFS benefit in metastatic TNBC
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospital,…
Apr 21, 2025, 16:59 | Blog
Amol Akhade: Antibody-Drug Conjugates in SCLC
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Apr 18, 2025, 13:39 | Drugs
Amol Akhade: First-line treatment options for NSCLC with uncommon EGFR mutations
Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn: "First-line…
Apr 16, 2025, 17:55 | Blog
Amol Akhade: Should CDK4/6 inhibitors be standard in early HR+/HER2– breast cancer?
Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:…
Apr 16, 2025, 08:15 | Blog
Amol Akhade: Comparison of Sacituzumab Govitecan and Sacituzumab Tirumotecan in mTNBC
Amol Akhade, Senior Medical and Hemato-Oncologist based in Mumbai, India, shared a post on LinkedIn:…
Apr 14, 2025, 13:33 | Blog
Amol Akhade: What are top websites used by Oncologist all over the world as per AI?
Amol Akhade, a Senior Medical and Hemato-Oncologist based in Mumbai, India, shared insights about Tarlatamab…
Apr 14, 2025, 12:14 | Blog
Amol Akhade: Important Sessions to Watch at ESMO Breast 2025 in Munich
Amol Akhade, Senior consultant of Medical oncology and Heamto oncology at Reliance Hospitals, shared on…
Apr 10, 2025, 12:41 | Science
Amol Akhade: BARCODE1 study - Hype or hope in PRS-guided prostate cancer screening?
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Apr 6, 2025, 11:41 | Blog
Amol Akhade: Trial Comparison - Ember3, Emerald and Post monarch
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Apr 2, 2025, 07:12 | Blog
Amol Akhade Seeks Expert Opinions on EV Plus Pembro Dosing for High-Risk Patients
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Mar 31, 2025, 15:22 | Societies
Highlights from ELCC 2025
The European Lung Cancer Congress (ELCC) 2025 held from 26–29 March in Paris, France, brought…
Mar 30, 2025, 12:14 | Blog
Amol Akhade: Will Laura trial show OS benifit at 60 % maturity?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Mar 30, 2025, 10:05 | Societies
Highlights from ELCC Day 4
The European Lung Cancer Congress (ELCC 2025) takes place in Paris from March 26-29, 2025, bringing together leading…
Mar 29, 2025, 16:52 | Societies
Highlights from ELCC Day 3
The European Lung Cancer Congress (ELCC 2025) takes place in Paris from March 26-29, 2025, bringing together leading…
Mar 26, 2025, 08:55 | Blog
Amol Akhade: Why should oncologists who are not into Academic institutions publish scientific papers?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Mar 26, 2025, 03:36 | Insight
Amol Akhade: Immune Checkpoint Inhibitors are under phase 3 trial in China
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Mar 17, 2025, 12:42 | Blog
Amol Akhade: Letters to editor is best part of any journal
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
Mar 11, 2025, 08:46 | Blog
Amol Akhade: Matterhorn Trial positive for EFS
Amol Akhade, Senior Consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Feb 19, 2025, 22:53 | Blog
Amol Akhade: Deepseek vs ChatGPT which one is better for oncology clincial problems?
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Feb 15, 2025, 22:55 | Societies
Highlights From Day 2 of ASCOGU25
The ASCO Genitourinary Cancers Symposium (ASCOGU25) is an annual event organized by the American Society of Clinical Oncology…
Feb 8, 2025, 12:17 | Blog
Amol Akhade: What is interesting in ASCO GU25
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Feb 4, 2025, 13:56 | Blog
Amol Akhade: We all are united in our shared goal of reducing cancer burden
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 29, 2025, 21:39 | Blog
Amol Akhade: Oligometastatic Esophageal Gastric cancers
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 28, 2025, 06:52 | Blog
Amol Akhade: How to manage rare GI cancers in 2025?
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics shared a post on…
Jan 27, 2025, 09:44 | Blog
Amol Akhade: Much awaited data from Checkmate 8HW
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 26, 2025, 21:55 | Blog
Adjuvant chemotherapy vs Adjuvant CTRT in Gallbladder cancer
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared on X: "Adjuvant chemotherapy vs…
Jan 26, 2025, 07:35 | Blog
Amol Akhade: Additon of trastuzumab With or without Pertuzumab in her2 postive stomach cancer
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, posted on X: "Innovation…
Jan 25, 2025, 14:26 | Insight
Highlights of ASCOGI25 Day 1
The 2025 ASCO Gastrointestinal (GI) Cancers Symposium is taking place from Thursday, January 23 to…
Jan 24, 2025, 14:12 | Insight
Amol Akhade: Do we need phase 3 clinical trials for oncology drug approvals?
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 23, 2025, 16:34 | Blog
Amol Akhade: Happy to be listed as one of the featured voice for ASCO GI 25
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, posted on LinkedIn: "Happy…
Jan 23, 2025, 14:32 | Blog
Amol Akhade: Does CTRT improve outcomes in gall bladder cancer?
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared the following on…
Jan 23, 2025, 14:32 | Blog
Amol Akhade: Intraperitoneal chemotherapy may hold promise for gastric cancer
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared the following on X:…
Jan 23, 2025, 12:47 | Insight
Amol Akhade: CAR-T Data for CRC in ASCO 24
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 23, 2025, 09:43 | Insight
Amol Akhade: Interesting results on subcutaneous Amivantamab in CRC
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 21, 2025, 15:59 | Insight
Amol Akhade's review on oncology practices among 172 oncologists worldwide
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 20, 2025, 13:56 | Opinion
Amol Akhade: Do oncologists from LMICs and HICs treat and read about only certain solid tumors or all of them?
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 19, 2025, 13:52 | Insight
Amol Akhade: Datopotomab deruxtecan got approved for HR+ HER2- MBC in the third line
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on…
Jan 16, 2025, 13:08 | Opinion
Amol Akhade: OS difference in first line Cdk inhibitors plus AI, amongst Palbociclib, Ribociclib and abemaciclib in MBC
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
Jan 13, 2025, 19:28 | Blog
Amol Akhade: Does anyone have any data on post-progression therapy of the control arm of the Adriatic trial?
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Jan 9, 2025, 03:44 | Insight
Amol Akhade: Mariposa shows significant OS benifit
Amol Akhade, A Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance…
Jan 7, 2025, 11:59 | Science
Amol Akhade: What is interesting in ASC0GI 25?
Amol Akhade, a Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance…
Jan 6, 2025, 14:53 | Blog
Amol Akhade: Should oncologist treat own 1st and 2nd degree relatives themselves?
Amol Akhade, a Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance…
Jan 3, 2025, 12:20 | Insight
Amol Akhade: Progress made in outcomes of metastatic cervical cancer over the years
Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on LinkedIn: “Progress made…
Dec 29, 2024, 10:02 | Blog
Amol Akhade: How as an oncologist you give emotional closure to family after demise of the patient?
Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X: "How as…
Dec 28, 2024, 11:14 | Science
Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial
Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X: "Tislelizumab gets…
Dec 27, 2024, 17:38 | Blog
Long-Term Follow-Up and Overall Survival in NRG258 by Daniela E Matei et al.
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 27, 2024, 16:49 | Blog
Amol Akhade: Reading as an Oncologist never ends
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 26, 2024, 15:03 | Insight
Amol Akhade: Adjuvant nivolumab in Muscle-Invasive Urothelial Carcinoma
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 25, 2024, 20:28 | Blog
Amol Akhade: My wishlist from Santa Claus and from 2025 in oncology
Amol Akhade shared on LinkedIn: "My wishlist from Santa Claus and from 2025 in oncology ,…
Dec 25, 2024, 17:26 | Science
Adjuvant nivolumab in Muscle-Invasive Urothelial Carcinoma
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 25, 2024, 03:35 | Blog
Amol Akhade: Use of Dostarlimab plus niraparib in first line Advanced Ovarian Cancer
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 24, 2024, 00:32 | Blog
Amol Akhade: Physicians should accept materialistic gifts?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 19, 2024, 01:55 | Blog
Amol Akhade: How oncologists keep themselves updated?
Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on LinkedIn: "With numerous…
Dec 17, 2024, 19:57 | Blog
Amol Akhade: What after Immunotherapy?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 16, 2024, 17:51 | Insight
Best of 2024 SABCS - San Antonio Breast Cancer Symposium
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 16, 2024, 11:45 | Blog
Amol Akhade: How do you keep yourself updated with the latest information?
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 16, 2024, 04:11 | Insight
Highlights from Day 4 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 15, 2024, 10:57 | Blog
Interesting results from the exploratory biomarker analysis of KN-522 study
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, reshared a post on…
Dec 15, 2024, 10:10 | Insight
Amol Akhade: How to treat metastatic breast cancer at the end of 2024
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 15, 2024, 01:17 | Blog
Amol Akhade: How to treat metastatic breast cancer at the end of 2024
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 13, 2024, 18:50 | Opinion
Amol Akhade: What IO combination will u prefer for first-line Advanced BTC?
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 13, 2024, 15:52 | Blog
SOLTI-2103 VALENTINE Trial: Phase II Trial of Neoadjuvant Patritumab Deruxtecan vs. Chemotherapy for High-Risk HR+/HER2- Early Breast Cancer
Neoadjuvant treatment for high-risk HR+/HER2- early breast cancer (EBC) remains challenging, with recurrence risks persisting…
Dec 11, 2024, 19:39 | Blog
Amol Akhade: What Immune Oncology plus chemo combination will u prefer for first line Advanced BTC ?
Amol Akhade shared a post on LinkedIn: "Final Results. What Immune Oncology plus chemo combination…
Dec 11, 2024, 19:12 | Insight
Highlights from Day 1 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 10, 2024, 06:28 | Blog
Amol Akhade: Survey for advanced biliary tract cancer treatment
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Dec 5, 2024, 11:19 | Blog
Amol Akhade: Real world evidence matters
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance, posted the…
Dec 5, 2024, 11:01 | Insight
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for NSCLC and Pancreatic Adenocarcinoma
On December 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for…
Dec 3, 2024, 03:53 | Blog
Amol Akhade: Insights into Resistance Mechanisms for EGFR TKI in NSCLC
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance, posted the…
Nov 27, 2024, 18:59 | Insight
Amol Akhade: New press release on the Skyscraper 01 trial
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance, shared…
Nov 25, 2024, 16:47 | Blog
Amol Akhade: Interesting discussion on new RCC data in 2024
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post…
Nov 24, 2024, 12:56 | Insight
Amol Akhade: Zanidatamab approved by US FDA for advanced BTC with IHC 3+ for second line
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Nov 24, 2024, 09:16 | Blog
Amol Akhade: What is FAPI Scan?
Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on LinkedIn about recent…
Nov 23, 2024, 13:32 | Blog
Amol Akhade: Do you use oncology apps for clinical practice ?
Amol Akhade shared on LinkedIn: "Do u use oncology apps for clinical practice ? There are…
Nov 21, 2024, 21:36 | Blog
Amol Akhade: Metastatic colorectal cancer - third line and beyond
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Nov 21, 2024, 21:27 | Blog
Amol Akhade: Current treatment and data of Esophageal cancer
Amol Akhade, senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Nov 17, 2024, 01:07 | Blog
Amol Akhade: Oncologists' perspectives on DYPD mutation testing before using drugs like Capecitabine and 5 FU
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
Nov 16, 2024, 15:44 | Blog
Amol Akhade: Nice review about role of CAR-T in solid tumors
Amol Akhade posted on X about recent paper by R.A. Saez et al., titled "Autologous…
Nov 14, 2024, 13:29 | Blog
Amol Akhade about the role of CAR-T in solid tumors
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals,…
12
All: 169 Posts: 1 - 100
Special Coverage